Analisi di costo della terapia con celecoxib vs FANS tradizionali nell’artrosi in Italia
- First Online:
- Cite this article as:
- Lucioni, C., Chiroli, S., Roggeri, D. et al. Pharmacoeconomics-Ital-Res-Articles (2003) 5: 23. doi:10.1007/BF03320601
Cost-analysis of a 6-week cycle of therapy with celecoxib vs conventional NSAIDs in ostheoarthritis in Italy
To estimate the cost in the Italian National Health Service (INHS) perspective of a 6-week treatment course with celecoxib vs NSAIDs in ostheoarthritis patients.
A decision-tree analysis with a 6-week time-frame.
Main outcome measures and results
Costs included the acquisition cost of celecoxib 200 mg/day and of a basket of the first ten prescribed NSAIDs in Italy during the year 2000. Probabilities of side effects were derived from clinical trials comparing celecoxib vs NSAIDs and adjusted for 6-week exposure. Costs to treat the adverse events and probability of hospitalization were derived from a previous study conducted in Italy among GPs. Sensitivity and treshold analyses were conducted to test the robustness of the model. In the 6-week period, celecoxib resulted the less expensive strategy vs NSAIDs (€ 72,35 vs 78,63). Probability of serious events with NSAIDs was most critical for the results and the cost-effectiveness of the new therapy was correlated to the risk of serious events with NSAIDs.
According to our study results, celecoxib represents a cost-effective first-line strategy alternative to NSAIDs for the symptomatic therapy of ostheoarthritis in Italy.